Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview

Cerenome

10/08/2026 13:49

Plus Therapeutics Inc CNSY.OQ CNSY.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026
The Austin Texas-based  company is expected to report a 20.1% decrease in revenue to $1.11 million from $1.39 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Plus Therapeutics Inc is for a loss of 91 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Plus Therapeutics Inc is $37.50, about 879.1% above its last closing price of $3.83
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.87
-0.88
-1.05
Missed
-19.3
Dec. 31 2026
-0.75
-0.81
-1.04
Missed
-27.7
Sep. 30 2025
-0.48
-0.50
-1.00
Missed
-100​
Jun. 30 2025
-1.71
-2.25
0.50
Beat
122.2
​​Mar. 31 2025
-4.00
-3.67
-29.75
Missed
-711.3
Dec. 31 2024
-10.75
-12.42
-12.25
Beat
1.3​
Sep. 30 2024
-12.67
-14.06
-9.25
Beat
34.2
Jun. 30 2024
-11.59
-13.25
-14.00
Missed
-5.7
This summary was machine generated August 10 at 12:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)